FOYA winners announced

Published: 21-Jan-2011
Manufacturing Finance

Six pharmaceutical manufacturing facilities in Europe and the US win award categories

Six pharmaceutical manufacturing facilities in Germany, Switzerland, Sweden, and the US have won category awards in the annual Facility of the Year Awards (FOYA). A seventh facility received an Honourable Mention.

Pfizer Health won the Facility of the Year Award for Operational Excellence at its Project Pegasus – Bio 7 manufacturing facility in Strängnäs, Sweden. This microbial drug substance production plant manufactures two legacy Pfizer hormone treatments, Genotropin and Somavert. Pfizer scientists developed a manufacturing process with virtually identical unit operations that could be used for both products.

Project Pegasus won this category for Pfizer’s ability to bring a new facility online with added capacity without increasing staff numbers or extending shift patterns. This was achieved by incorporating a high degree of flexibility into the facility design. The project team also minimised manual interactions in the process.

Control system recipes were developed that enhanced the efficiency of this biotech operation. Targeted output of the facility was previously 2 batches per week, but as a result of their focus on Operational Excellence, the facility currently has the capacity to produce 3.5 batches per week.

F. Hoffman – La Roche took the Process Innovation category award for its “MyDose” clinical supply facility in Kaiseraugst, Switzerland.

MedImmune won for Project Execution at its Frederick Manufacturing Center (FMC) expansion facility in Frederick, Maryland, US, while the Facility Integration category award went to Merck and Company for its Global Clinical Supplies Manufacturing, Packaging and Warehouse expansion project in Summit, New Jersey, US.

Novartis Vaccines and Diagnostics took the Equipment Innovation category award for its “MARS Project” facility in Marburg, Germany.

The sixth winner was Pfizer Manufacturing Deutschland, which won the Sustainability category for its SPRING & E-MAP (Strategic Plant Restructuring & Energy Master Plan) project in Freiburg, Germany.

Shire HGT received an Honourable Mention for its Project Atlas, Building 400 facility in Lexington, Massachusetts, US.

Now in its seventh year, the Facility of the Year Awards, sponsored by ISPE, Interphex and Pharmaceutical Processing magazine in the US, recognise state-of-the-art pharmaceutical manufacturing projects that incorporate new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing medicines.

The Overall Facility of the Year award will be presented during ISPE’s 2011 Annual Meeting, which takes place from 6–9 November in Grapevine, Texas, US.

See more

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Read more
Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
  4. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  5. Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Finance

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Manufacturing

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment
Finance

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America
Finance

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline

Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC therapy for advanced prostate cancer
Subscribe now